Beacon Investment Advisory Services Inc. Has $12.35 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Beacon Investment Advisory Services Inc. reduced its stake in Regeneron Pharmaceuticals by 10.4%, owning 23,515 shares valued at approximately $12.35 million at the end of the most recent quarter.
• Regeneron Pharmaceuticals reported $12.89 earnings per share for the most recent quarter, significantly exceeding analysts' expectations of $8.43, and achieved a revenue of $3.68 billion.
• Recent analyst ratings for Regeneron include upgrades to "strong-buy" and "buy", with a consensus target price of $817.67.

Beacon Investment Advisory Services Inc. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 10.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,515 shares of the biopharmaceutical company's stock after selling 2,744 shares during the period. Beacon Investment Advisory Services Inc.'s holdings in Regeneron Pharmaceuticals were worth $12,345,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Harrell Investment Partners LLC acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $1,055,000. Fifth Third Bancorp lifted its holdings in shares of Regeneron Pharmaceuticals by 31.8% during the second quarter. Fifth Third Bancorp now owns 10,134 shares of the biopharmaceutical company's stock worth $5,320,000 after purchasing an additional 2,443 shares during the period. Sheets Smith Wealth Management lifted its holdings in shares of Regeneron Pharmaceuticals by 4.5% during the second quarter. Sheets Smith Wealth Management now owns 1,281 shares of the biopharmaceutical company's stock worth $673,000 after purchasing an additional 55 shares during the period. Eaton Financial Holdings Company LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $494,000. Finally, Cardinal Capital Management lifted its holdings in shares of Regeneron Pharmaceuticals by 3.5% during the second quarter. Cardinal Capital Management now owns 8,316 shares of the biopharmaceutical company's stock worth $4,366,000 after purchasing an additional 280 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $576.98 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,070.00. The firm has a fifty day simple moving average of $569.25 and a 200 day simple moving average of $573.47. The company has a market capitalization of $61.15 billion, a PE ratio of 14.54, a P/E/G ratio of 1.81 and a beta of 0.35. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter last year, the firm earned $11.56 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% on a year-over-year basis. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of recent research reports. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Morgan Stanley reiterated an "overweight" rating and set a $761.00 price target (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Canaccord Genuity Group reiterated a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Finally, Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.